Pathstone Family Office’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $10.6M | Buy |
181,425
+126,810
| +232% | +$7.77M | 0.08% | 166 |
|
|
2023
Q2 | $3.69M | Buy |
54,615
+7,405
| +16% | +$497K | 0.05% | 207 |
|
|
2023
Q1 | $3.33M | Sell |
47,210
-124,970
| -73% | -$8.81M | 0.05% | 201 |
|
|
2022
Q4 | $9.02M | Buy |
172,180
+56,312
| +49% | +$4.25M | 0.08% | 186 |
|
|
2022
Q3 | $8.46M | Buy |
115,868
+94,771
| +449% | +$6.87M | 0.08% | 152 |
|
|
2022
Q2 | $1.63M | Buy |
21,097
+14,142
| +203% | +$1.08M | 0.04% | 240 |
|
|
2022
Q1 | $624K | Buy |
6,955
+1,222
| +21% | +$82K | 0.01% | 466 |
|
|
2021
Q4 | $357K | Sell |
5,733
-2,674
| -32% | -$157K | 0.01% | 659 |
|
|
2021
Q3 | $499K | Buy |
8,407
+1,274
| +18% | +$83.9K | 0.01% | 513 |
|
|
2021
Q2 | $477K | Sell |
7,133
-893
| -11% | -$58.2K | 0.01% | 481 |
|
|
2021
Q1 | $508K | Buy |
8,026
+1,877
| +31% | +$117K | 0.02% | 338 |
|
|
2020
Q4 | $381K | Buy |
6,149
+3,700
| +151% | +$228K | 0.02% | 199 |
|
|
2020
Q3 | $147K | Buy |
2,449
+549
| +29% | +$33K | 0.02% | 228 |
|
|
2020
Q2 | $112K | Buy |
1,900
+200
| +12% | +$12K | 0.01% | 213 |
|
|
2020
Q1 | $95K | Sell |
1,700
-1,000
| -37% | -$61.1K | 0.01% | 227 |
|
|
2019
Q4 | $1.73M | Buy |
2,700
+670
| +33% | +$38.4K | 0.02% | 164 |
|
|
2019
Q3 | $104K | Sell |
2,030
-670
| -25% | -$31.5K | 0.01% | 193 |
|
|
2019
Q2 | $122K | Buy |
2,700
+1,600
| +145% | +$74.5K | 0.01% | 242 |
|
|
2019
Q1 | $52K | Buy |
1,100
+371
| +51% | +$18.5K | 0.01% | 298 |
|
|
2018
Q4 | $38K | Buy |
729
+29
| +4% | +$1.56K | 0.01% | 206 |
|
|
2018
Q3 | $43K | Hold |
700
| – | – | 0.01% | 108 |
|
|
2018
Q2 | $39K | Hold |
700
| – | – | 0.03% | 84 |
|
|
2018
Q1 | $44K | Hold |
700
| – | – | 0.02% | 110 |
|
|
2017
Q4 | $43K | Hold |
700
| – | – | 0.02% | 64 |
|
|
2017
Q3 | $45K | Sell |
700
-7
| -1% | -$409 | 0.04% | 75 |
|
|
2017
Q2 | $39K | Sell |
707
-131
| -16% | -$7.13K | 0.02% | 213 |
|
|
2017
Q1 | $45K | Buy |
+838
| New | +$46K | 0.02% | 187 |
|
|
2016
Q4 | – | Sell |
-791
| Closed | -$43K | – | 112 |
|
|
2016
Q3 | $43K | Sell |
791
-76
| -9% | -$4.88K | 0.04% | 68 |
|
|
2016
Q2 | $64K | Buy |
867
+700
| +419% | +$49.5K | 0.06% | 51 |
|
|
2016
Q1 | $11K | Buy |
+167
| New | +$10.5K | 0.02% | 98 |
|
|
2015
Q4 | – | Sell |
-60
| Closed | -$4K | – | 99 |
|
|
2015
Q3 | $4K | Buy |
+60
| New | +$3.81K | 0.01% | 130 |
|
|
2013
Q4 | – | Sell |
-43
| Closed | -$2K | – | 219 |
|
|
2013
Q3 | $2K | Buy |
+43
| New | +$1.89K | 0.01% | 276 |
|
Other funds holding BMY
Pathstone Family Office's BMY Position: Q3 2023 in Review
Pathstone Family Office increased its Bristol-Myers Squibb (BMY) stake by 232% in Q3 2023, buying an estimated $7.77M and bringing the position to 181,425 shares worth $10.6M. The position accounts for 0.08% of the portfolio, ranked #166.
Pathstone Family Office first reported a position in BMY in Q3 2013 and has held it in 32 quarters since. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.
- Pathstone Family Office held 181,425 shares of Bristol-Myers Squibb worth $10.6M as of Q3 2023.
- Pathstone Family Office bought 126,810 Bristol-Myers Squibb shares in Q3 2023, an estimated $7.77M.
- Bristol-Myers Squibb made up 0.08% of Pathstone Family Office's portfolio in Q3 2023, its #166 holding.
- Pathstone Family Office first reported a position in Bristol-Myers Squibb in Q3 2013 and has held it in 32 quarters since.
- 2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.